Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16230728 | 1.00 | TP53 (0.37) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL16230660 | 1.00 | TP53 (0.37) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL14443274 | 0.97 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL14443275 | 0.97 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL8976097 | 0.97 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL16805015 | 0.94 | UGT2B7 (0.33) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL11911962 | 0.88 | — | — | |
| SCHEMBL3416717 | 0.88 | — | — | |
| SCHEMBL9221102 | 0.79 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL22430438 | 0.77 | CPN1 (0.35) | LMNAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110294972-A | A kind of ink | 深圳TCL工业研究院有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-110294972-A | A kind of ink | 深圳TCL工业研究院有限公司 | 2019-10-01 | — | — | CN | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-12-29 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | TP53 4666/4885KDM4E 3919/4885GMNN 4597/4885 |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | TP53 782/4885KDM4E 244/4885GMNN 3332/4885 |
| US-20160075695-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | TP53 814/4885KDM4E 255/4885GMNN 3388/4885 |
| US-20160376261-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | TP53 782/4885KDM4E 244/4885GMNN 3332/4885 |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | TP53 794/4885KDM4E 249/4885GMNN 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.